Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$525.28 USD

525.28
842,078

-0.66 (-0.13%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $525.55 +0.27 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks News

LabCorp's (LH) New Antigen Test to Spot Active COVID-19 Virus

LabCorp's (LH) new antigen test is the newest development to detect COVID-19 infection at every single stage, from diagnostic testing to vaccination trails.

Should Value Investors Buy McKesson (MCK) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The Zacks Analyst Blog Highlights: Align Technology, Henry Schein, McKesson Corp and Becton, Dickinson and Co

The Zacks Analyst Blog Highlights: Align Technology, Henry Schein, McKesson Corp and Becton, Dickinson and Co

4 Dental Stocks to Watch on Likely Industry Turnaround

The dental equipment market seems ready to grow as it continues to recover from the COVID-19 pandemic slump, making it prudent to look at names like Henry Schein (HSIC) and McKesson (MCK)

Here's Why You Should Hold on to McKesson (MCK) Stock Now

McKesson (MCK) continues to benefit from the multi-year strategic growth initiative and strength in the Distribution Solutions segment.

Sheraz Mian headshot

Top Stock Reports for Oracle, Medtronic & AMD

Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Medtronic (MDT), and Advanced Micro Devices (AMD).

McKesson (MCK) Earnings and Revenues Beat Estimates in Q3

McKesson's (MCK) fiscal third-quarter 2021 results benefit from strong performance at Medical-Surgical Solutions segment.

McKesson (MCK) Q3 Earnings and Revenues Surpass Estimates

McKesson (MCK) delivered earnings and revenue surprises of 11.38% and 1.16%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

MedTech Stock Earnings on Feb 2: IDXX, MCK & More

In Q4, MedTech stocks are expected to have gained from month-wise sales rebound in many states and regions. However, international sales might have been dampened.

McKesson (MCK) to Report Q3 Earnings: What's in the Offing?

McKesson's (MCK) fiscal third-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.

Thermo Fisher (TMO) Expands in Viral Vector With Henogen Buyout

The addition of Henogen's manufacturing capabilities in Europe complement Thermo Fisher's (TMO) four development and manufacturing sites in North America.

Can McKesson (MCK) Keep the Earnings Surprise Streak Alive?

McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BD (BDX) Posts Upbeat Preliminary Fiscal First Quarter Results

BD (BDX) projects its fiscal Q1 revenues to surge from the year-ago figure, primarily on the back of high demand for its COVID-19 diagnostic tests

Intuitive Surgical (ISRG) Up on Solid Preliminary Q4 Results

Intuitive Surgical (ISRG) posts solid fourth-quarter and full-year 2020 result driven mainly by da Vinci procedure volume growth.

Pacific Biosciences (PACB) Releases Preliminary Q4 Revenues

Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320.

Here's Why You Should Invest in McKesson (MCK) Stock Now

McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.

DexCom (DXCM) Posts Solid Preliminary Q4 and 2020 Revenues

DexCom (DXCM) posts solid fourth-quarter and full-year 2020 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.

Nevro (NVRO) Posts Weak Preliminary Q4 and 2020 Revenues

Nevro's (NVRO) preliminary worldwide Q4 revenues are expected to decline from the year-ago quarter's figure.

Sweta Killa headshot

4 Sector ETFs & Stocks to Bet on Q4 Earnings

Sectors with positive earnings growth in Q4 include autos (86.3% earnings growth), construction (27.2%), basic materials (7.6%), medical (6.3%), and aerospace (4.4%).

Why You Must Add Merit Medical (MMSI) Stock to Your Portfolio

Investor optimism is high on Merit Medical (MMSI) stock, courtesy of solid prospects.

The Zacks Analyst Blog Highlights: McKesson, Cardinal Health, Becton, Dickinson and Co and Hill-Rom Holdings

The Zacks Analyst Blog Highlights: McKesson, Cardinal Health, Becton, Dickinson and Co and Hill-Rom Holdings

Urmimala Biswas headshot

4 Dividend-Paying Undervalued MedTech Stocks for Gains in 2021

Here we discuss four dividend-paying value stocks, MCK, CAH, BDX and HRC, which though trading cheap now, have solid chances of a rebound in the second half of 2021.

AmerisourceBergen (ABC), WBA Ink Deal to Focus on Core Arms

AmerisourceBergen (ABC) and Walgreens (WBA) enter into a key strategic deal to boost focus on core businesses, while extending their partnership.

NextGen's (NXGN) Platform Gets Adopted by FPA Women's Health

FPA Women's Health utilizes NextGen's (NXGN) Virtual Visits, which are integral to the company's Patient Experience Platform

Why You Should Retain Veeva (VEEV) in Your Portfolio Now?

Investor confidence/optimism is high on Veeva (VEEV) stock, driven by its solid prospects.